Grzegorz Marek Karwacki
Since its introduction in 2008 Renal Denervation (RDN) has garnered enthusiasts among physicians, patients and the medical device industry. In December 2013 a research and consulting firm predicted a growth of the global renal denervation market in the next 6 years from approximately 3,000 procedures in 2012 up to nearly 40,000 by 2019 (representing a value of over $170 million). Even though the optimism was toned down D??er 5 years of trial applications of RDN (initial expectations mentioned a market on the order of a billion dollars by 2020), the hype surrounding this invasive therapy method for patients with treatment-resistant hypertension was still on the rise. ?Ls all changed in January 2014 when Medtronic announced that its pivotal SYMPLICITY HTN-3 trial failed to meet its primary efficacy endpoint.
Published Date: 2021-01-30; Received Date: 2021-01-13